chloroquine has been researched along with Retinal Diseases in 270 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine maculopathy is a major complication observed during prophylactic treatment of malaria." | 8.79 | [Chloroquine maculopathy and prevention of malaria]. ( Balo, KP; Mensah, A; Mihluedo, H, 1996) |
| "Chloroquine retinopathy (CR) is a major complication of long-term malaria prophylaxis (LTMP) causing permanent visual dysfunction and occasionally blindness." | 7.71 | Case report: Retinopathy after malaria prophylaxis with chloroquine. ( Bertagnolio, S; Camilli, G; Tacconelli, E; Tumbarello, M, 2001) |
| "Chloroquine continues to have a limited role in the chemoprophylaxis against malaria." | 7.69 | No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. ( Contoreggi, CS; Frame, JD; Frankenfield, DL; Lange, WR; Moriarty-Sheehan, M, 1994) |
| "270 consecutive patients with rheumatoid arthritis who had received chloroquine therapy were examined ophthalmologically for toxic retinal lesions." | 7.65 | Chloroquine retinopathy in patients with rheumatoid arthritis. ( Elman, A; Gullberg, R; Nilsson, E; Rendahl, I; Wachtmeister, L, 1976) |
| "Chloroquine retinopathy was defined using previously published criteria." | 5.30 | Detection of color vision defects in chloroquine retinopathy. ( Easterbrook, M; Hovis, JK; Vu, BL, 1999) |
| "To check the ability of microperimetry to detect early retinal damage in patients with rheumatism taking hydroxychloroquine (HCQ), chloroquine (CQ), or both, and to describe the microperimetric alterations attributable to these drugs and their correlation with some clinical variables." | 5.17 | Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. ( Beltrán-Catalán, E; Epifanio, I; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Verdejo-Gimeno, C; Victoria Ibañez, M, 2013) |
| "Chloroquine (CQ) and hydroxycholorquine (HCQ) have been used widely for the treatment of rheumatoid arthritis and other similar inflammatory diseases since the early 50s." | 4.82 | Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. ( Tzekov, R, 2005) |
| "Chloroquine maculopathy is a major complication observed during prophylactic treatment of malaria." | 4.79 | [Chloroquine maculopathy and prevention of malaria]. ( Balo, KP; Mensah, A; Mihluedo, H, 1996) |
| "This paper discusses the use of chloroquine and hydroxychloroquine in the treatment of rheumatoid arthritis and systemic lupus erythematosus, it summarizes their retinotoxic risk, and it outlines the diagnostic techniques used to evaluate patients treated with these medications." | 4.78 | Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. ( Aylward, JM, 1993) |
| " The prolonged use of chloroquine and hydroxychloroquine can cause hyperpigmentation in the skin, oral mucosa and retinal pigment epithelium, which in turn can trigger toxicity in this epithelium, which in some cases causes vision loss." | 3.96 | Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. ( Chacón-Dulcey, V; Frías, J; González, N; López-Labady, J; Pérez Alfonzo, R; Tirado, W; Villarroel-Dorrego, M, 2020) |
| "To determine whether patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) taking chloroquine or hydroxychloroquine are regularly visiting eye care providers and being screened for maculopathy." | 3.80 | Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. ( Blachley, TS; Edwards, P; Lee, PP; Nika, M; Stein, JD, 2014) |
| "A 60-year-old woman presented for routine ocular examination with a medical history of severe rheumatoid arthritis, for which she had been receiving 3 mg chloroquine (CQ) per kilogram for the past 17 years." | 3.76 | Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient. ( Angi, M; Romano, F; Romano, MR; Romano, V; Valldeperas, X, 2010) |
| "Considering the normality of the electro-oculogram, we can easily conclude that the electro-oculogram is not sensible to detect chloroquine maculopathy and that reported reductions may occur due to the course of the rheumatoid arthritis itself." | 3.74 | Electrophysiologic findings in chloroquine maculopathy. ( Halfeld Furtado de Mendonça, R; Maia, OO; Yukihiko Takahashi, W, 2007) |
| "We report the case of a 51-year-old woman who presented with bilateral progressive deterioration in vision after taking chloroquine for severe rheumatoid arthritis for 10 years." | 3.73 | Chloroquine-induced bull's eye maculopathy. ( Lai, WW; Lam, DS, 2005) |
| "Chloroquine retinopathy (CR) is a major complication of long-term malaria prophylaxis (LTMP) causing permanent visual dysfunction and occasionally blindness." | 3.71 | Case report: Retinopathy after malaria prophylaxis with chloroquine. ( Bertagnolio, S; Camilli, G; Tacconelli, E; Tumbarello, M, 2001) |
| "Chloroquine continues to have a limited role in the chemoprophylaxis against malaria." | 3.69 | No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. ( Contoreggi, CS; Frame, JD; Frankenfield, DL; Lange, WR; Moriarty-Sheehan, M, 1994) |
| "Delayed-onset chloroquine retinopathy was diagnosed in a patient seven years after cessation of treatment by a total dose of 730 g of chloroquine for rheumatoid arthritis." | 3.67 | Delayed-onset chloroquine retinopathy. ( Ehrenfeld, M; Merin, S; Nesher, R, 1986) |
| "270 consecutive patients with rheumatoid arthritis who had received chloroquine therapy were examined ophthalmologically for toxic retinal lesions." | 3.65 | Chloroquine retinopathy in patients with rheumatoid arthritis. ( Elman, A; Gullberg, R; Nilsson, E; Rendahl, I; Wachtmeister, L, 1976) |
| "Chloroquine and hydroxychloroquine are widely used in diseases of connective tissue, especially in rheumatoid arthritis and systemic lupus erythematosus." | 3.65 | [Complications in chloroquin therapy]. ( Siegmeth, W, 1975) |
| " Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect." | 2.72 | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. ( Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A, 2021) |
| "Effective treatment of retinal diseases with adeno-associated virus (AAV)-mediated gene therapy is highly dependent on the proportion of successfully transduced cells." | 2.66 | Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. ( Barnard, AR; Chandler, LC; MacLaren, RE; McClements, ME; Xue, K; Yusuf, IH, 2020) |
| "criteria for the diagnosis of systemic lupus erythematosus, 43 were selected for study because each had been treated for at least two years with antimalarials, but had not received antimalarials for at least one subsequent year." | 2.64 | The efficacy of antimalarials in systemic lupus erythematosus. ( Gresham, GE; Rothfield, NF; Rudnicki, RD, 1975) |
| " A higher dosage per kg body mass, long therapy duration, presence of keratopathy and renal or hepatic dysfunction are probably associated with an increased risk to develop a maculopathy/retinopathy." | 2.45 | [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. ( Pluta, JP; Rüther, K, 2009) |
| " Patients should be dosed on the basis of ideal body weight (not actual body weight) to reduce the incidence of macular toxicity." | 2.40 | Detection and prevention of maculopathy associated with antimalarial agents. ( Easterbrook, M, 1999) |
| " The dosage parameters associated with retinopathy are still uncertain as well as the best way to screen for it but the dosage/kg body weight appears to be important." | 2.39 | Retinopathy and antimalarial drugs--the British experience. ( Spalton, DJ, 1996) |
| " Retinopathy can be avoided by observing a maximum daily dosage of 3." | 2.38 | [Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs]. ( Ochsendorf, FR; Runne, U, 1991) |
| " Many of these reviews, while generally excellent, have propagated some apparent misconceptions by disregarding or de-emphasizing data suggesting that irreversible retinal toxicity due to antimalarials can be easily avoided by judicious daily dosage and regular ophthalmologic follow-up." | 2.36 | Antimalarials and ophthalmologic safety. ( Olansky, AJ, 1982) |
| " The accumulation of a nontoxic drug in the eye is not necessarily of clinical significance, but ocular damage can occur in patients on long-term tricyclic agents when the amount, duration, and frequency of dosage are sufficiently high." | 2.36 | Ocular accumulation and toxicity of certain systemically administered drugs. ( Mason, CG, 1977) |
| "Chloroquine-induced maculopathy may progress years after drug cessation and an apparent period of visual stability." | 1.46 | Delayed progression of bull's eye maculopathy. ( Jain, NG; Jain, S, 2017) |
| " Established risk factors are duration and dosage of treatment while the involvement of genetic factors contributing to toxic maculopathy is largely unclear." | 1.42 | Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). ( Bergholz, R; Grassmann, F; Jägle, H; Mändl, J; Ruether, K; Weber, BH, 2015) |
| " Retinal toxicity may represent a rare adverse reaction to zoledronic acid, but this case suggests that caution should be used when administering this medication to patients with compromised retinal integrity." | 1.40 | Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy. ( Bursztyn, LL; Masri, M; Sheidow, TG, 2014) |
| "Rheumatoid arthritis (RA) patients who had taken CQ for at least 6 months and stable CQ dosage for at least 2 months were included." | 1.39 | Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. ( Arromdee, E; Boonprasert, R; Chandranipapongse, W; Chatsiricharoenkul, S; Chiowchanwisawakit, P; Danwiriyakul, W; Katchamart, W; Koolvisoot, A; Nilganuwong, S; Pongnarin, P; Ruangvaravate, N; Srinonprasert, V, 2013) |
| "Chloroquine maculopathy has a major impact on the vision-related health status of affected patients, emphasizing the need for its anticipation." | 1.39 | [Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy]. ( Bergholz, R; Joussen, AM; Rüther, K; Schroeter, J; Tillack, H, 2013) |
| "Chloroquine (CQ) is a widely prescribed anti-malarial agent and is also prescribed to treat autoimmune diseases." | 1.38 | A novel role for α-tocopherol transfer protein (α-TTP) in protecting against chloroquine toxicity. ( Arai, H; Hagihara, Y; Kono, N; Rotzoll, DE; Shichiri, M; Shimanaka, Y; Tamai, H; Tanito, M; Yoshida, Y, 2012) |
| "The prior recommendation emphasized dosing by weight." | 1.37 | Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. ( Kellner, U; Lai, TY; Lyons, JS; Marmor, MF; Mieler, WF, 2011) |
| " In patients in whom the daily dosage of hydroxychloroquine could be estimated (12 of 13), when using actual body weight, 8 were taking 6." | 1.37 | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. ( Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG, 2011) |
| " Individual and weight-adapted dosing is especially essential for chloroquine." | 1.36 | Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. ( Bergholz, R; Rüther, K; Schroeter, J, 2010) |
| " It is thought that variability in the presentation of chloroquine retinopathy may be the result of perturbations in drug bioavailability subsequent to oral ingestion." | 1.35 | Retinal toxicity of chloroquine hydrochloride administered by intraperitoneal injection. ( Gaynes, BI; Grostern, R; Perlman, J; Torczynski, E; Varro, Z, 2008) |
| " A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year." | 1.34 | [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. ( Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007) |
| " Adverse events observed after treatment with chloroquine or prednisone (chloroquine maculopathy,cataract, glaucoma) are related to dosage and duration of the treatment." | 1.34 | [Ocular changes and general condition in lupus erythematosus (SLE)--own observation]. ( Brydak-Godowska, J, 2007) |
| "Chloroquine treatment was discontinued." | 1.33 | [Severe chloroquine- and hydroxychloroquine-induced retinopathy]. ( Bui Quoc, E; Crochet, M; Dufier, JL; Ingster-Moati, I; Orssaud, C; Roche, O, 2006) |
| " For patients using chloroquine, the correlation between RNFL measurements and chloroquine dosage was assessed." | 1.33 | Retinal nerve fibre layer thickness measurements in patients using chloroquine. ( Bonanomi, MT; Dantas, NC; Medeiros, FA, 2006) |
| "All cases arose because of failure by physicians to avoid dosing above published safe levels." | 1.31 | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. ( Browning, DJ, 2002) |
| "Chloroquine retinopathy was defined using previously published criteria." | 1.30 | Detection of color vision defects in chloroquine retinopathy. ( Easterbrook, M; Hovis, JK; Vu, BL, 1999) |
| "Chloroquine has been prescribed for the treatment of various diseases." | 1.30 | Ocular toxicity of chloroquine among Thai patients. ( Janwitayanujit, S; Kunavisarut, S; Nantiruj, K; Puavilai, S; Ruangkanchanasetr, S; Sriwong, ST; Timpatanapong, P; Totemchokchyakarn, K; Vatanasuk, M, 1999) |
| "chloroquine) was low." | 1.29 | [Macular complications of synthetic antimalarials. Apropos of a case]. ( Ballion, JC; Bazin, S; Bourguignon, G; Ducousso, F; Kovalski, JL; Labrouze, JM; Saliou, G, 1995) |
| "Corneal opacity, reversible retinal lipidosis and irreversible receptor cell degeneration are known to occur after long-term treatment with chloroquine." | 1.29 | Chloroquine-induced lipidosis in the rat retina: a functional and morphological study. ( Bredehorn, T; Duncker, G; Schmiederer, M, 1995) |
| "Chloroquine retinopathy is a severe toxic retinal impairment which may result in loss of vision by alterations of the retinal pigment epithelium and photoreceptors." | 1.29 | Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730. ( Bonhomme, B; Braquet, P; Cluzel, J; Doly, M; Millerin, M, 1993) |
| "Chloroquine was found to form lamellar lysosome-like structures within the photoreceptive layer, as well as the pigment epithelium and neurooretinal layers." | 1.29 | Lipidemic effect as a manifestation of chloroquine retinotoxicity. ( Abdel-Khalek, LR; el-Sayed, NK; Gaafar, KM; Ramadan, GA, 1995) |
| " Chronic administration of chloroquine (20 days) caused an overall lengthening of the duration of the ERG b-wave, together with delayed peaking." | 1.28 | Effect of Gingko biloba extract (EGb 761) on chloroquine induced retinal alterations. ( Besse, G; Doly, M; Droy-Lefaix, MT; Vennat, JC, 1992) |
| "Chloroquine retinopathy is a severe toxic retinal impairment which may result in loss of vision by alterations of the pigmentary epithelium and photoreceptors." | 1.28 | [Involvement of PAF (Platelet-Activating Factor) in chloroquine-induced retinopathy]. ( Braquet, P; Doly, M; Meyniel, G; Millerin, M, 1992) |
| " I therefore consider these dosage rates safe, since they are below the threshold of retinal toxicity." | 1.27 | Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. ( Mackenzie, AH, 1983) |
| " Identical doses do not always produce the same effect and toxic symptoms have developed after a dosage ranging from 86 to 760 g." | 1.27 | [Routine monitoring of patients treated with synthetic antimalarials]. ( Bechetoille, A; Douche, C; Ebran, JM, 1983) |
| "Chloroquine retinopathy was produced experimentally in the eye of the albino corydoras (one of the tropical fish) by daily administration of chloroquine (0." | 1.27 | Experimental chloroquine retinopathy. ( Matsumura, M; Ohkuma, M; Tsukahara, I, 1986) |
| "Four cases of irreversible bilateral scotomas were detected in 8 eyes of 4 patients with normal static and kinetic fields in 7 of the 8 eyes." | 1.27 | The sensitivity of Amsler grid testing in early chloroquine retinopathy. ( Easterbrook, M, 1985) |
| "Treatment with chloroquine (with a dose similar to that used in human anti-rheumatic therapy) over the same period, resulted in the appearance of numerous membranous cytoplasmic bodies in the retinal ganglion cells of mice and cats." | 1.26 | Lack of correlation between melanin affinity and retinopathy in mice and cats treated with chloroquine or flunitrazepam. ( Keller, P; Kovács, E; Kuhn, H; Steiger, A, 1981) |
| "Chloroquine retinopathy is a drug disease that can be prevented." | 1.26 | [The therapy with synthetic antimalarial drugs controlled by fluorescence electroretinography (author's transl)]. ( Carpi, R; Cordella, M; Franchi, A; Neri, F, 1980) |
| "Chloroquine was administered intramuscularly 5 days a week to rhesus monkeys for as long as 4 1/2 years." | 1.26 | Chloroquine retinopathy in the rhesus monkey. ( Bergsma, D; Hopkins, JL; Huxsoll, D; Kolb, H; Rosenthal, AR, 1978) |
| "Serious visual impairment related to chloroquine rarely occurs if the daily dose does not exceed 250 mg." | 1.26 | Chloroquine retinopathy: is there a safe daily dose? ( Marks, JS, 1982) |
| "Human babesiosis (Nantucket fever) is a rare, tick-borne intraerythrocytic parasitic disease characterized by fever, lymphadenopathy, arthralgias, and hemolytic anemia." | 1.26 | Ocular findings in human babesiosis (Nantucket fever). ( Eagle, RC; Ortiz, JM, 1982) |
| "We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years." | 1.25 | Ocular manifestations of juvenile rheumatoid arthritis. ( Bellows, AR; Bienfang, DC; Chylack, LT; Stillman, JS, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 130 (48.15) | 18.7374 |
| 1990's | 34 (12.59) | 18.2507 |
| 2000's | 38 (14.07) | 29.6817 |
| 2010's | 52 (19.26) | 24.3611 |
| 2020's | 16 (5.93) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen Hoang, AT | 4 |
| Lee, H | 4 |
| Lee, SJ | 4 |
| Arnon, R | 1 |
| Hilely, A | 1 |
| Almeida-Brasil, CC | 3 |
| Hanly, JG | 3 |
| Urowitz, M | 3 |
| Clarke, AE | 3 |
| Ruiz-Irastorza, G | 3 |
| Gordon, C | 3 |
| Ramsey-Goldman, R | 3 |
| Petri, MA | 3 |
| Ginzler, EM | 3 |
| Wallace, DJ | 3 |
| Bae, SC | 3 |
| Romero-Diaz, J | 3 |
| Dooley, MA | 3 |
| Peschken, C | 3 |
| Isenberg, D | 3 |
| Rahman, A | 3 |
| Manzi, S | 3 |
| Jacobsen, S | 3 |
| Lim, SS | 3 |
| van Vollenhoven, R | 3 |
| Nived, O | 3 |
| Jönsen, A | 3 |
| Kamen, DL | 3 |
| Aranow, C | 3 |
| Sánchez-Guerrero, J | 3 |
| Gladman, DD | 3 |
| Fortin, PR | 3 |
| Alarcon, GS | 3 |
| Merrill, JT | 3 |
| Kalunian, K | 3 |
| Ramos-Casals, M | 3 |
| Steinsson, K | 3 |
| Zoma, A | 3 |
| Askanase, AD | 3 |
| Khamashta, M | 3 |
| Bruce, IN | 3 |
| Inanc, M | 3 |
| Lukusa, L | 3 |
| Bernatsky, S | 4 |
| Mauget-Faÿsse, M | 3 |
| Sukkarieh, G | 3 |
| Jebrane, H | 3 |
| Lafolie, J | 3 |
| Alonso, AS | 3 |
| Laumonier, E | 3 |
| Derrien, S | 3 |
| Le Guern, V | 3 |
| Behar Cohen, F | 3 |
| Thevenin, S | 3 |
| Auge, E | 3 |
| Guillaume, J | 3 |
| Vasseur, V | 3 |
| Costedoat-Chalumean, N | 3 |
| Cardoso, MH | 1 |
| Hall, MJ | 1 |
| Burgoyne, T | 1 |
| Fale, P | 1 |
| Storm, T | 1 |
| Escrevente, C | 1 |
| Antas, P | 1 |
| Seabra, MC | 1 |
| Futter, CE | 1 |
| Rickmann, A | 1 |
| Al-Nawaiseh, S | 1 |
| Ramirez, L | 1 |
| Röhrig, S | 1 |
| Ladewig, M | 1 |
| Szurman, P | 1 |
| Szurman, G | 1 |
| Bertoli, F | 1 |
| Šuštar, M | 1 |
| Jarc Vidmar, M | 1 |
| Perovšek, D | 1 |
| Brecelj, J | 1 |
| Markelj, Š | 1 |
| Jaki Mekjavić, P | 1 |
| Šuput, D | 1 |
| Tomšič, M | 1 |
| Isola, M | 1 |
| Battistella, C | 1 |
| Lanzetta, P | 1 |
| Hawlina, M | 1 |
| Pineton de Chambrun, M | 1 |
| Settegrana, C | 1 |
| Dorgham, K | 1 |
| Fenneteau, O | 1 |
| Goujon, JM | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Chacón-Dulcey, V | 1 |
| López-Labady, J | 1 |
| Villarroel-Dorrego, M | 1 |
| Frías, J | 1 |
| Tirado, W | 1 |
| González, N | 1 |
| Pérez Alfonzo, R | 1 |
| Marmor, MF | 6 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Chandler, LC | 1 |
| Yusuf, IH | 5 |
| McClements, ME | 1 |
| Barnard, AR | 1 |
| MacLaren, RE | 1 |
| Xue, K | 1 |
| Nuzbrokh, Y | 1 |
| Jauregui, R | 1 |
| Oh, JK | 1 |
| Moazami, G | 1 |
| Sparrow, JR | 1 |
| Tsang, SH | 2 |
| Foot, B | 2 |
| Lotery, AJ | 4 |
| Fambuena-Muedra, I | 1 |
| Jiménez-García, M | 1 |
| Hershko, S | 1 |
| Altemir-Gómez, I | 1 |
| Tobarra-López, A | 1 |
| Guiot, A | 2 |
| Couturier, M | 2 |
| Tebib, JG | 2 |
| Abouaf, L | 2 |
| Coury, F | 2 |
| Jain, S | 1 |
| Jain, NG | 1 |
| Wiacek, MP | 1 |
| Bobrowska-Snarska, D | 1 |
| Lubiński, W | 1 |
| Brzosko, M | 1 |
| Modrzejewska, M | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Ledingham, JM | 1 |
| MacPhie, E | 1 |
| Galloway, J | 2 |
| Giocanti-Aurégan, A | 1 |
| Couturier, A | 1 |
| Girmens, JF | 1 |
| Le Mer, Y | 1 |
| Massamba, N | 2 |
| Barreau, E | 1 |
| Audo, I | 1 |
| Ardern-Jones, MR | 1 |
| Watson, SL | 1 |
| Yelf, C | 1 |
| Burdon, MA | 1 |
| Bishop, PN | 1 |
| Kosic Knez, N | 1 |
| Šiško, K | 1 |
| Holc, I | 1 |
| Pahor, D | 1 |
| Pahor, A | 1 |
| Gracner, T | 1 |
| Ma, X | 2 |
| Zhang, Y | 1 |
| Zhu, D | 1 |
| Chen, Z | 1 |
| Xu, M | 1 |
| He, L | 2 |
| Shi, T | 1 |
| Huang, L | 1 |
| Zou, J | 1 |
| Tsang, AC | 2 |
| Ahmadi, S | 1 |
| Hamilton, J | 2 |
| Gao, J | 1 |
| Virgili, G | 2 |
| Coupland, SG | 2 |
| Gottlieb, CC | 2 |
| Chiowchanwisawakit, P | 1 |
| Nilganuwong, S | 1 |
| Srinonprasert, V | 1 |
| Boonprasert, R | 1 |
| Chandranipapongse, W | 1 |
| Chatsiricharoenkul, S | 1 |
| Katchamart, W | 1 |
| Pongnarin, P | 1 |
| Danwiriyakul, W | 1 |
| Koolvisoot, A | 1 |
| Arromdee, E | 1 |
| Ruangvaravate, N | 1 |
| Yaylali, SA | 1 |
| Sadigov, F | 1 |
| Erbil, H | 1 |
| Ekinci, A | 1 |
| Akcakaya, AA | 1 |
| Ascaso, FJ | 1 |
| Rodríguez, NA | 1 |
| San Miguel, R | 1 |
| Huerva, V | 1 |
| Martínez-Costa, L | 2 |
| Victoria Ibañez, M | 1 |
| Murcia-Bello, C | 2 |
| Epifanio, I | 2 |
| Verdejo-Gimeno, C | 2 |
| Beltrán-Catalán, E | 2 |
| Marco-Ventura, P | 2 |
| Kellner, S | 3 |
| Weinitz, S | 3 |
| Farmand, G | 1 |
| Kellner, U | 8 |
| Bae, EJ | 1 |
| Kim, KR | 1 |
| Park, SP | 1 |
| Chang, S | 1 |
| Easterbrook, M | 18 |
| Trentini, FJ | 1 |
| Ibañez, MV | 1 |
| Nika, M | 1 |
| Blachley, TS | 1 |
| Edwards, P | 1 |
| Lee, PP | 1 |
| Stein, JD | 1 |
| Bursztyn, LL | 1 |
| Masri, M | 1 |
| Sheidow, TG | 1 |
| Abdelkhalek, R | 1 |
| Hanafi, Y | 1 |
| Bergholz, R | 4 |
| Rüther, K | 5 |
| Schroeter, J | 4 |
| von Sonnleithner, C | 1 |
| Salchow, DJ | 1 |
| Melles, RB | 2 |
| Ahmadi Pirshahid, S | 1 |
| Grassmann, F | 1 |
| Mändl, J | 1 |
| Jägle, H | 1 |
| Ruether, K | 1 |
| Weber, BH | 1 |
| Ganne, P | 1 |
| Srinivasan, R | 1 |
| Oluleye, TS | 1 |
| Babalola, Y | 1 |
| Ijaduola, M | 1 |
| Sanabria, MR | 1 |
| Toledo-Lucho, SC | 1 |
| Sellam, A | 1 |
| Le Hoang, P | 1 |
| Bodaghi, B | 2 |
| Kasturi, N | 1 |
| Lai, TY | 2 |
| Mieler, WF | 3 |
| Pawlak-Buś, K | 1 |
| Gaca-Wysocka, M | 1 |
| Grzybowski, A | 1 |
| Leszczyński, P | 1 |
| Murray, JJ | 1 |
| Lee, MS | 1 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Angi, M | 1 |
| Romano, V | 1 |
| Valldeperas, X | 1 |
| Romano, F | 1 |
| Romano, MR | 1 |
| Nebbioso, M | 1 |
| Grenga, R | 1 |
| Karavitis, P | 1 |
| Pasadhika, S | 1 |
| Fishman, GA | 1 |
| Nogueira, HM | 1 |
| Gama, RD | 1 |
| Pluta, JP | 1 |
| Yan, L | 1 |
| He, D | 1 |
| Lu, H | 1 |
| Suansilpong, A | 1 |
| Uaratanawong, S | 1 |
| Kobak, S | 1 |
| Deveci, H | 1 |
| Karkanová, M | 1 |
| Matusková, V | 1 |
| Vlková, E | 1 |
| Dosková, H | 1 |
| Uhmannová, R | 1 |
| Xiaoyun, MA | 1 |
| Dongyi, HE | 1 |
| Linping, HE | 1 |
| Michaelides, M | 1 |
| Stover, NB | 1 |
| Francis, PJ | 1 |
| Weleber, RG | 1 |
| Raster, M | 1 |
| Horn, F | 1 |
| Jünemann, A | 1 |
| Rosa, AA | 1 |
| Souza, GS | 1 |
| Gomes, BD | 1 |
| Lima, MG | 1 |
| Silveira, LC | 1 |
| Kremers, J | 1 |
| Lyons, JS | 1 |
| SCHERBEL, AL | 1 |
| MACKENZIE, AH | 2 |
| NOUSEK, JE | 1 |
| ATDJIAN, M | 1 |
| Hickley, NM | 1 |
| Al-Maskari, A | 1 |
| McKibbin, M | 1 |
| Shichiri, M | 1 |
| Kono, N | 1 |
| Shimanaka, Y | 1 |
| Tanito, M | 1 |
| Rotzoll, DE | 1 |
| Yoshida, Y | 1 |
| Hagihara, Y | 1 |
| Tamai, H | 1 |
| Arai, H | 1 |
| Missner, S | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Tillack, H | 2 |
| Joussen, AM | 1 |
| Burnett, HK | 1 |
| Somani, R | 1 |
| Neubauer, AS | 1 |
| Samari-Kermani, K | 1 |
| Schaller, U | 1 |
| Welge-Lübetaen, U | 1 |
| Rudolph, G | 1 |
| Berninger, T | 1 |
| Pineau, C | 1 |
| Joseph, L | 1 |
| Clarke, A | 1 |
| CARLBERG, O | 1 |
| ERICSON, LA | 1 |
| ELLSWORTH, RJ | 1 |
| ZELLER, RW | 1 |
| RICHARDS, RD | 1 |
| WILSON, WR | 1 |
| WALTER, CJ | 1 |
| GEORGE, JB | 1 |
| MITCHELL, PC | 1 |
| GOURAS, P | 3 |
| GUNKEL, RD | 2 |
| JONES, J | 1 |
| OKUN, E | 1 |
| BERNSTEIN, H | 1 |
| VON SALLMANN, L | 1 |
| JANSEN, LM | 2 |
| PRICE, L | 1 |
| RUBIN, M | 1 |
| BERNSTEIN, HN | 3 |
| ZVAIFLER, NJ | 2 |
| HENKIND, P | 2 |
| CARR, RE | 2 |
| SIEGEL, IM | 1 |
| GINSBERG, J | 1 |
| MCCONNELL, DG | 1 |
| WACHTEL, J | 1 |
| HAVENER, WH | 1 |
| LAMERS, WP | 2 |
| MEIER-RUGE, W | 2 |
| LLOYD, LA | 1 |
| HILTZ, JW | 1 |
| DALE, AJ | 1 |
| PARKHILL, EM | 1 |
| LAYTON, DD | 1 |
| BUTLER, I | 2 |
| HENKES, HE | 2 |
| LANGHOF, H | 1 |
| GEYER, G | 1 |
| BARTHELMES, H | 1 |
| HOBBS, HE | 1 |
| SORSBY, A | 1 |
| FREEDMAN, A | 1 |
| MAYER, W | 1 |
| ORMROD, JN | 1 |
| Tristano, AG | 1 |
| Falcón, L | 1 |
| Willson, M | 1 |
| de Oca, IM | 1 |
| Rivett, K | 1 |
| Araiza-Casillas, R | 1 |
| Cárdenas, F | 1 |
| Morales, Y | 1 |
| Cardiel, MH | 1 |
| Toler, SM | 1 |
| Mahon, GJ | 1 |
| Anderson, HR | 1 |
| Gardiner, TA | 1 |
| McFarlane, S | 1 |
| Archer, DB | 1 |
| Stitt, AW | 1 |
| Lai, WW | 1 |
| Lam, DS | 1 |
| Whitelaw, D | 1 |
| Jessop, S | 1 |
| Bui Quoc, E | 2 |
| Ingster-Moati, I | 2 |
| Rigolet, MH | 1 |
| Chosidow, O | 1 |
| Liu, W | 1 |
| Sharma, S | 1 |
| Tzekov, R | 1 |
| Bonanomi, MT | 1 |
| Dantas, NC | 1 |
| Medeiros, FA | 1 |
| Renner, AB | 1 |
| Crochet, M | 1 |
| Orssaud, C | 1 |
| Dufier, JL | 1 |
| Roche, O | 1 |
| Beraru, V | 1 |
| Ferreras, A | 1 |
| Pinilla, I | 1 |
| Abecia, E | 1 |
| Pajarín, AB | 1 |
| Honrubia, FM | 1 |
| Halfeld Furtado de Mendonça, R | 1 |
| Maia, OO | 1 |
| Yukihiko Takahashi, W | 1 |
| Foerster, J | 1 |
| Berndt, S | 1 |
| Brydak-Godowska, J | 1 |
| Wilson, W | 1 |
| Ritenour, RJ | 1 |
| Cruess, AF | 2 |
| Mishra, AV | 1 |
| Flach, AJ | 1 |
| Gaynes, BI | 1 |
| Torczynski, E | 1 |
| Varro, Z | 1 |
| Grostern, R | 1 |
| Perlman, J | 1 |
| Kuhn, H | 1 |
| Keller, P | 1 |
| Kovács, E | 1 |
| Steiger, A | 1 |
| Portnoy, JZ | 1 |
| Callen, JP | 1 |
| Hellner, KA | 1 |
| Gauri, KK | 1 |
| Amoni, SS | 1 |
| Al Khamis, AR | 1 |
| Douche, C | 1 |
| Bechetoille, A | 1 |
| Ebran, JM | 1 |
| Hart, WM | 1 |
| Burde, RM | 1 |
| Johnston, GP | 1 |
| Drews, RC | 1 |
| Lanham, JG | 1 |
| Hughes, GR | 1 |
| Bunch, TW | 1 |
| O'Duffy, JD | 1 |
| Olansky, AJ | 1 |
| Marks, JS | 1 |
| Ortiz, JM | 1 |
| Eagle, RC | 1 |
| Bentsi-Enchill, KO | 2 |
| Stilma, JS | 1 |
| Carpi, R | 1 |
| Cordella, M | 1 |
| Franchi, A | 1 |
| Neri, F | 1 |
| Ohki, K | 1 |
| Heckenlively, JR | 1 |
| Martin, D | 1 |
| Levy, J | 1 |
| Ducousso, F | 1 |
| Ballion, JC | 1 |
| Kovalski, JL | 1 |
| Labrouze, JM | 1 |
| Bazin, S | 1 |
| Bourguignon, G | 1 |
| Saliou, G | 1 |
| Duncker, G | 1 |
| Schmiederer, M | 1 |
| Bredehorn, T | 1 |
| Lange, WR | 1 |
| Frankenfield, DL | 1 |
| Moriarty-Sheehan, M | 1 |
| Contoreggi, CS | 1 |
| Frame, JD | 1 |
| Aylward, JM | 1 |
| Jeddi, A | 1 |
| Ben Osman, N | 1 |
| Daghfous, F | 1 |
| Bouguila, H | 1 |
| Charfi, O | 1 |
| Ayed, S | 1 |
| Magulike, NO | 1 |
| Ihenacho, HN | 2 |
| Ike, VO | 1 |
| Doly, M | 3 |
| Cluzel, J | 1 |
| Millerin, M | 2 |
| Bonhomme, B | 1 |
| Braquet, P | 2 |
| Ochsendorf, FR | 5 |
| Runne, U | 5 |
| Goerz, G | 1 |
| Zrenner, E | 1 |
| Spalton, DJ | 1 |
| Rynes, RI | 2 |
| Gaafar, KM | 2 |
| Abdel-Khalek, LR | 2 |
| el-Sayed, NK | 2 |
| Ramadan, GA | 1 |
| Felton, JM | 1 |
| Waddell, KM | 1 |
| Balo, KP | 1 |
| Mensah, A | 1 |
| Mihluedo, H | 1 |
| Yoshida, T | 1 |
| Fukatsu, R | 1 |
| Tsuzuki, K | 1 |
| Aizawa, Y | 1 |
| Hayashi, Y | 1 |
| Sasaki, N | 1 |
| Takamaru, Y | 1 |
| Fujii, N | 1 |
| Takahata, N | 1 |
| Wölfelschneider, P | 1 |
| Kohen, L | 1 |
| Wiedemann, P | 1 |
| Hanafy, LK | 1 |
| Eggers, I | 1 |
| Krastel, H | 1 |
| Vu, BL | 1 |
| Hovis, JK | 1 |
| Esdaile, JM | 1 |
| Puavilai, S | 1 |
| Kunavisarut, S | 1 |
| Vatanasuk, M | 1 |
| Timpatanapong, P | 1 |
| Sriwong, ST | 1 |
| Janwitayanujit, S | 1 |
| Nantiruj, K | 1 |
| Totemchokchyakarn, K | 1 |
| Ruangkanchanasetr, S | 1 |
| Kraus, H | 1 |
| Foerster, MH | 1 |
| Shroyer, NF | 1 |
| Lewis, RA | 1 |
| Lupski, JR | 1 |
| Bertagnolio, S | 1 |
| Tacconelli, E | 1 |
| Camilli, G | 1 |
| Tumbarello, M | 1 |
| Vázquez-Del Mercado, M | 1 |
| Muñoz-Valle, JF | 1 |
| Santos, A | 1 |
| Bernard-Medina, AG | 1 |
| Martínez-Bonilla, G | 1 |
| Paczka, JA | 1 |
| Ruiz-García, H | 1 |
| Orozco-Alcalá, J | 1 |
| Orozco-Barocio, G | 1 |
| Quezada-Arellano, D | 1 |
| Gurrola-Díaz, C | 1 |
| Nuño-González, P | 1 |
| Best-Aguilera, CR | 1 |
| Chávez-Castellanos, R | 1 |
| Panduro, A | 1 |
| Browning, DJ | 1 |
| Farjo, AA | 1 |
| Jaeger, W | 1 |
| Drenckhahn, D | 1 |
| Lüllmann-Rauch, R | 1 |
| Rosenthal, AR | 1 |
| Kolb, H | 1 |
| Bergsma, D | 1 |
| Huxsoll, D | 1 |
| Hopkins, JL | 1 |
| Meyer, JJ | 1 |
| Korol, S | 2 |
| Babel, J | 2 |
| Ferrier, R | 1 |
| Lierse, W | 1 |
| Dubois, EL | 2 |
| Klinghardt, GW | 1 |
| Mason, CG | 1 |
| Brinkley, JR | 1 |
| Ryan, SJ | 1 |
| Yamagishi, N | 1 |
| Nagata, M | 1 |
| François, J | 4 |
| Chovet, M | 1 |
| Vedy, J | 1 |
| Fauxpoint, B | 1 |
| Vingtain, P | 1 |
| Tokuda, K | 2 |
| Kelsey, JH | 2 |
| Lakanapichonchat, T | 1 |
| Martin, LJ | 1 |
| Bergen, RL | 1 |
| Dobrow, HR | 1 |
| Tamai, A | 1 |
| Holland, MG | 1 |
| Kubota, Y | 1 |
| Popert, AJ | 1 |
| Elman, A | 2 |
| Gullberg, R | 2 |
| Nilsson, E | 2 |
| Rendahl, I | 2 |
| Wachtmeister, L | 2 |
| Lowes, M | 1 |
| van Lith, GH | 1 |
| Mak, GT | 1 |
| Wijnands, H | 1 |
| Chylack, LT | 1 |
| Bienfang, DC | 1 |
| Bellows, AR | 1 |
| Stillman, JS | 1 |
| Zinn, KM | 1 |
| Greenseid, DZ | 1 |
| Rudnicki, RD | 1 |
| Gresham, GE | 1 |
| Rothfield, NF | 1 |
| Thompson, SW | 1 |
| Brodin, U | 1 |
| Trojan, HJ | 1 |
| Siegmeth, W | 1 |
| Droy-Lefaix, MT | 1 |
| Vennat, JC | 1 |
| Besse, G | 1 |
| Meyniel, G | 1 |
| Ruiz, RS | 1 |
| Saatci, OA | 1 |
| Trope, G | 1 |
| Niemeyer, G | 1 |
| Früh, B | 1 |
| Lozier, JR | 1 |
| Friedlaender, MH | 1 |
| Raines, MF | 1 |
| Bhargava, SK | 1 |
| Rosen, ES | 1 |
| Magulike, E | 1 |
| Havens, PL | 1 |
| Splaingard, ML | 1 |
| Bousounis, D | 1 |
| Hoffman, GM | 1 |
| Larricart, P | 1 |
| Matsumura, M | 1 |
| Ohkuma, M | 1 |
| Tsukahara, I | 1 |
| Banks, CN | 1 |
| Ivanina, TA | 1 |
| Lebedeva, MN | 1 |
| Sakina, NL | 1 |
| Babizhaev, MA | 1 |
| Ermakova, VN | 1 |
| Ehrenfeld, M | 1 |
| Nesher, R | 1 |
| Merin, S | 1 |
| Schachat, AP | 1 |
| Nicholl, J | 1 |
| Augsburger, JJ | 1 |
| Finbloom, DS | 1 |
| Silver, K | 1 |
| Newsome, DA | 1 |
| Gunkel, R | 1 |
| Guzel, H | 1 |
| Hattat, N | 1 |
| Oguz, V | 1 |
| Yazici, H | 1 |
| Gold, DH | 1 |
| Ramsey, MS | 1 |
| Fine, BS | 1 |
| Goldhammer, Y | 1 |
| Smith, JL | 1 |
| Futenma, M | 1 |
| Seki, T | 1 |
| Brown, RK | 1 |
| de Rouck, A | 2 |
| Cambie, E | 2 |
| de Laey, JJ | 2 |
| Appleton, B | 1 |
| Wolfe, MS | 1 |
| Mishtowt, GI | 1 |
| Stein, R | 2 |
| Godel, V | 2 |
| Nemet, P | 2 |
| Parizot, H | 1 |
| Schmid, H | 1 |
| Koller, F | 1 |
| Deutman, AF | 1 |
| Thaler, A | 1 |
| Heilig, P | 1 |
| Slezak, H | 1 |
| Bertrand, JJ | 1 |
| Biard, L | 1 |
| Perdriel, G | 1 |
| Chevaleraud, J | 1 |
| Vignat, JP | 1 |
| Branchevskaia, SIa | 1 |
| Petrohelos, MA | 1 |
| Weise, EE | 1 |
| Yannuzzi, LA | 1 |
| Cerasoli, JR | 1 |
| Morandi, GA | 1 |
| el-Shewy, TM | 1 |
| Hassan, AH | 1 |
| Einin, GI | 1 |
| Hamid, HA | 1 |
| Hache, JC | 1 |
| Turut, P | 1 |
| Dufour, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Posterior Segment Evaluation of Patients With Systemic Lupus Erythematosus Using Optical Coherence Tomography and Optical Coherence Tomography Angiography[NCT04866615] | 150 participants (Anticipated) | Observational | 2021-06-04 | Recruiting | |||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Metabolic Effects of Hydroxychloroquine[NCT02026232] | 21 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to COVID-19 & loss of funding) | |||
| Genotype - Phenotype Study of Patients With Plaquenil-induced Retinal Toxicity[NCT01145196] | 300 participants (Anticipated) | Observational | 2010-08-23 | Recruiting | |||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
determined by fasting blood glucose performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline Glucose (mg/dL) | Follow-up Glucose (mg/dL) | |
| Hydroxychloroquine | 186.9 | 165.9 |
| Placebo | 163.1 | 158.8 |
determined by lipid profile with calculated LDL performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline - LDL (mg/dL) | Follow-up - LDL (mg/dL) | |
| Hydroxychloroquine | 90.4 | 72.4 |
| Placebo | 92.8 | 87.7 |
40 reviews available for chloroquine and Retinal Diseases
| Article | Year |
|---|---|
[Progressive maculopathy despite discontinuation of chloroquine treatment-multimodal imaging and review of the literature].
Topics: Chloroquine; Humans; Macular Degeneration; Multimodal Imaging; Prognosis; Retinal Diseases | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
Topics: Animals; Betacoronavirus; Chloroquine; Dependovirus; Genetic Therapy; Humans; Hydroxychloroquine; Im | 2020 |
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Topics: Antimalarials; Caregivers; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adver | 2021 |
What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mas | 2017 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary.
Topics: Chloroquine; Clinical Protocols; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine | 2018 |
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Hydroxychlo | 2015 |
[Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Disea | 2016 |
Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy.
Topics: Antimalarials; Chloroquine; Early Diagnosis; Electroretinography; Humans; Hydroxychloroquine; Malari | 2009 |
[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Dru | 2009 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Screening for antimalarial toxicity: current concepts.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2002 |
Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy.
Topics: Animals; Blindness; Chloroquine; Humans; Indomethacin; Oxidative Stress; Retina; Retinal Diseases; T | 2004 |
Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Humans; Hydr | 2005 |
[Drug-induced retinopathies].
Topics: Chloroquine; Humans; Phenothiazines; Piperazines; Purines; Retinal Diseases; Sildenafil Citrate; Sul | 2006 |
Ophthalmologic aspects of chloroquine and hydroxychloroquine therapy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Electroretinography; Eye; Humans; Hydroxychloroquine; | 1983 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
Disease-modifying drugs for progressive rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Azathioprine; Chloroquine; Cyclophosphamide; Gold; Gold Sodi | 1980 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1982 |
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retin | 1993 |
[Chloroquine retinopathy: avoidable by individualized daily dosing].
Topics: Adult; Child; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Retinal Dis | 1993 |
Retinopathy and antimalarial drugs--the British experience.
Topics: Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Ma | 1996 |
Ophthalmologic considerations in using antimalarials in the United States.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Safety; United States; Vis | 1996 |
[Chloroquine maculopathy and prevention of malaria].
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Macula Lutea; M | 1996 |
Detection and prevention of maculopathy associated with antimalarial agents.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mac | 1999 |
Antimalarials in the management of discoid and systemic lupus erythematosus.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Lupus Erythematosus, | 1978 |
Experimental neuropathology and clinical neurology of chloroquine side effects.
Topics: Animals; Axons; Chloroquine; Cytoplasmic Granules; Dose-Response Relationship, Drug; Ganglia, Spinal | 1978 |
Ocular accumulation and toxicity of certain systemically administered drugs.
Topics: Amitriptyline; Animals; Chloroquine; Cornea; Eye; Eye Diseases; Female; Haplorhini; Humans; Lens, Cr | 1977 |
Toxicology of the retinal pigment epithelium.
Topics: Animals; Chloroquine; Chlorpromazine; Dose-Response Relationship, Drug; Epithelium; Humans; Melanins | 1975 |
Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients.
Topics: Chloroquine; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Photography; Retinal Disea | 1991 |
[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].
Topics: Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Hydr | 1991 |
[Examination strategies in the diagnosis of drug-induced retinal damage].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Risk Factors; Vision Tests | 1989 |
Complications of antimalarial therapy.
Topics: Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Ciliary Body; Color Perception; Corneal D | 1989 |
Melanin: blackguard or red herring? Another look at chloroquine retinopathy.
Topics: Animals; Chloroquine; Humans; Melanins; Pharmacy and Therapeutics Committee; Retinal Diseases | 1987 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
Antimalarials in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Eruptions; Headache; Humans; Hydroxychloroquine; Placebos; | 1971 |
Ocular complications in rheumatic disorders.
Topics: Arthritis, Rheumatoid; Cataract; Chloroquine; Conjunctivitis; Eye Diseases; Glaucoma; Humans; Iritis | 1973 |
[What retinal structures are investigated using ERG and EOG? Morphological and functional correlation].
Topics: Acetates; Animals; Chloroquine; Electrooculography; Electroretinography; Glutamates; Glycine; Iodate | 1974 |
Effects of drugs on the retina.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chloroquine; Cinchona; Drug-Related Sid | 1971 |
4 trials available for chloroquine and Retinal Diseases
| Article | Year |
|---|---|
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Topics: Adult; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Electroretinography; Female; Fixa | 2013 |
Accuracy of Amsler grid in screening for chloroquine retinopathy.
Topics: Adult; Antirheumatic Agents; Chloroquine; Female; Humans; Male; Middle Aged; Predictive Value of Tes | 2010 |
Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Apolipoproteins E; Arthritis, Rheumatoid; Chloroquine | 2002 |
The efficacy of antimalarials in systemic lupus erythematosus.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; Dr | 1975 |
226 other studies available for chloroquine and Retinal Diseases
| Article | Year |
|---|---|
Casein kinase I inhibitor D4476 influences autophagy and apoptosis in chloroquine-induced adult retinal pigment epithelial-19 cells.
Topics: Apoptosis; Autophagy; Beclin-1; Casein Kinase I; Chloroquine; Humans; Proto-Oncogene Proteins c-bcl- | 2022 |
[CHLOROQUINE AND HYDROXYCHLOROQUINE TOXICITY].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Ginsenoside protopanaxadiol protects adult retinal pigment epithelial-19 cells from chloroquine by modulating autophagy and apoptosis.
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Chloroquine; Ginsenosides; Humans; Reactive Oxygen Species; R | 2022 |
Ginsenoside protopanaxadiol protects adult retinal pigment epithelial-19 cells from chloroquine by modulating autophagy and apoptosis.
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Chloroquine; Ginsenosides; Humans; Reactive Oxygen Species; R | 2022 |
Ginsenoside protopanaxadiol protects adult retinal pigment epithelial-19 cells from chloroquine by modulating autophagy and apoptosis.
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Chloroquine; Ginsenosides; Humans; Reactive Oxygen Species; R | 2022 |
Ginsenoside protopanaxadiol protects adult retinal pigment epithelial-19 cells from chloroquine by modulating autophagy and apoptosis.
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Chloroquine; Ginsenosides; Humans; Reactive Oxygen Species; R | 2022 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
Impaired Lysosome Reformation in Chloroquine-Treated Retinal Pigment Epithelial Cells.
Topics: Autophagy; Chloroquine; Epithelial Cells; Humans; Lysosomes; Phagocytosis; Retinal Diseases; Retinal | 2023 |
Electrophysiological and SD-OCT findings in patients receiving chloroquine therapy in relation to cumulative dosage and duration of treatment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloroquine; Duration of Therap | 2020 |
Systemic chloroquine intoxication: a hint from the peripheral blood smear.
Topics: Cardiomyopathies; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Neutropen | 2020 |
Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Hyperpigmen | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topi | 2020 |
Presumed Chloroquine Retinopathy With Short-term Therapy for Glioblastoma Multiforme.
Topics: Adult; Antirheumatic Agents; Brain Neoplasms; Chloroquine; Female; Fluorescein Angiography; Fundus O | 2020 |
The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary.
Topics: Chloroquine; Humans; Hydroxychloroquine; Ophthalmologists; Retinal Diseases; United Kingdom | 2021 |
Antimalarial drug retinopathy: A typical « Bull's eyes » appearance of fundus.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2018 |
Delayed progression of bull's eye maculopathy.
Topics: Aftercare; Aged; Antirheumatic Agents; Chloroquine; Disease Progression; Electroretinography; Female | 2017 |
Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine.
Topics: Adolescent; Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Retinal D | 2018 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythemato | 2018 |
Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Practice Guidelines as Topic | 2019 |
[Variability of chloroquine and hydroxychloroquine retinopathy among various ethnicities].
Topics: Antirheumatic Agents; Asian People; Chloroquine; Delayed Diagnosis; Early Diagnosis; Electroretinogr | 2018 |
[Spectral Domain Optical Coherence Tomographic Findings in Systemic Lupus erythematosus in Patients Treated with Chloroquine].
Topics: Chloroquine; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ret | 2019 |
Low dosage chloroquine protects retinal ganglion cells against glutamate-induced cell death.
Topics: Animals; Animals, Newborn; Antirheumatic Agents; Apoptosis; Blotting, Western; Cells, Cultured; Chlo | 2019 |
The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluo | 2019 |
Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy.
Topics: Antirheumatic Agents; Chloroquine; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Fe | 2013 |
Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Cohort Studies; Enzyme Inhibitors; Female; Humans; H | 2013 |
The "flying saucer" sign on spectral domain optical coherence tomography in chloroquine retinopathy.
Topics: Adult; Antirheumatic Agents; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Retinal Dis | 2013 |
Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation.
Topics: Aged; Antirheumatic Agents; Chloroquine; Disease Progression; Electroretinography; Epiretinal Membra | 2014 |
Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive optics scanning laser ophthalmoscopy.
Topics: Chloroquine; Diagnosis, Differential; Female; Humans; Image Enhancement; Lupus Erythematosus, System | 2014 |
RE: Microperimetry and the diagnosis of antimalarial maculopathy.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Disease | 2014 |
RE: Author reply:.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Disease | 2014 |
Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.
Topics: Aged; Ambulatory Care; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Color Perception Te | 2014 |
Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy.
Topics: Antirheumatic Agents; Bone Density Conservation Agents; Chloroquine; Diphosphonates; Female; Humans; | 2014 |
[Maculopathy in a lupus patient after taking antimalarial drugs].
Topics: Antimalarials; Chloroquine; Female; Fluorescein Angiography; Humans; Lupus Erythematosus, Systemic; | 2014 |
Influence of chloroquine intake on the multifocal electroretinogram in patients with and without maculopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Female; Humans; Middl | 2015 |
Hydroxychloroquine and the retina.
Topics: Ambulatory Care; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Female; | 2015 |
Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy).
Topics: Adult; Aged; Alleles; Antirheumatic Agents; ATP-Binding Cassette Transporters; Chloroquine; Female; | 2015 |
Chloroquine retinopathy.
Topics: Antirheumatic Agents; Chloroquine; Drug Substitution; Electroretinography; Humans; Lupus Erythematos | 2015 |
Chloroquine retinopathy: pattern of presentation in Ibadan, Sub-Sahara Africa.
Topics: Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Malaria; Male; Middle Aged; Nigeria; Retina | 2016 |
Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Follow-Up S | 2016 |
[Multimodal imaging of hydroxychloroquine and chloroquine retinopathy].
Topics: Adult; Atrophy; Chloroquine; Diagnostic Techniques, Ophthalmological; Drug Substitution; Female; Hum | 2016 |
Long-term continuation of chloroquine-induced retinal toxicity in rheumatoid arthritis despite drug cessation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Humans; Male; Middle | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). (Ophthalmology 2016;123:1386-1394).
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Ophthalmology; R | 2017 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Early Diagnosis; Female; Fixation, Ocular; | 2010 |
Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Enzyme Inhibitors; Female; Humans; Hydroxychloroquin | 2010 |
Images in clinical medicine. Bull's-eye maculopathy.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Ophth | 2009 |
Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Early Diagnosis; Electroretinography; Fluorescein An | 2009 |
Ocular fundus manifestation of two patients following long-term chloroquine therapy: a case report.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Female; Fluore | 2010 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; | 2010 |
[The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; M | 2010 |
Assessing chloroquine toxicity in RA patients using retinal nerve fibre layer thickness, multifocal electroretinography and visual field test.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Early Diagnosis; Electroret | 2010 |
Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Dose-Response Relatio | 2010 |
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy | 2011 |
Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chloroquine; Electroretinography; Female | 2011 |
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Age Factors; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Oph | 2011 |
Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy. A study of 741 patients treated with and without chloroquine drugs.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Chloroquine; Choroiditi | 1965 |
Chloroquine and hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vis | 2011 |
A novel role for α-tocopherol transfer protein (α-TTP) in protecting against chloroquine toxicity.
Topics: Animals; Antimalarials; Carrier Proteins; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; | 2012 |
Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophth | 2012 |
[Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].
Topics: Adult; Aged; Chloroquine; Health Status; Humans; Macula Lutea; Male; Mass Screening; Middle Aged; Ph | 2013 |
Clinically evident chloroquine toxicity undetected by multifocal electroretinogram.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Humans; Lup | 2012 |
New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological | 2003 |
Detecting chloroquine retinopathy: electro-oculogram versus colour vision.
Topics: Aging; Antirheumatic Agents; Chloroquine; Color Perception; Cornea; Electrooculography; Epidemiologi | 2003 |
Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.
Topics: Adult; Antimalarials; Antirheumatic Agents; Chloroquine; Cohort Studies; Drug Monitoring; Female; Gu | 2003 |
[Retinal complications after chloroquine treatment].
Topics: Chloroquine; Disease; Retina; Retinal Diseases | 1961 |
Chloroquine (Aralen)-induced retinal damage.
Topics: Chloroquine; Eye Injuries; Retina; Retinal Diseases | 1961 |
Retinopathy associated with chloroquine phosphate therapy.
Topics: Chloroquine; Disease; Retina; Retinal Diseases | 1961 |
Retinopathy following chloroquine therapy.
Topics: Chloroquine; Disease; Retina; Retinal Diseases | 1961 |
Chloroquine retinopathy. A further case.
Topics: Chloroquine; Disease; Retina; Retinal Diseases | 1962 |
Spatial differences in the human ERG.
Topics: Chloroquine; Disease; Electronic Data Processing; Electroretinography; Humans; Retina; Retinal Disea | 1962 |
Chloroquine retinopathy; a report of eight cases with ERG and dark-adaptation findings.
Topics: Chloroquine; Dark Adaptation; Humans; Retina; Retinal Diseases | 1963 |
Retinopathy after nivaquine treatment.
Topics: Chloroquine; Humans; Retina; Retinal Diseases; Retinal Vessels | 1962 |
Retinopathy associated with chloroquine.
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Humans; Lupus Erythematosus, Sys | 1961 |
THE EOG IN CHLOROQUINE AND OTHER RETINOPATHIES.
Topics: Albinism; Chloroquine; Color Vision Defects; Electrodiagnosis; Electrooculography; Electroretinograp | 1963 |
STUDIES ON THE PHARMACOLOGY OF CHLOROQUINE. RECOMMENDATIONS FOR THE TREATMENT OF CHLOROQUINE RETINOPATHY.
Topics: Ammonium Chloride; Chloroquine; Dimercaprol; Erythrocytes; Hematuria; Metabolism; Ophthalmology; Pha | 1963 |
EARLY CHLOROQUINE RETINOPATHY: CLINICAL AND FUNCTIONAL FINDINGS.
Topics: Chloroquine; Electroretinography; Ophthalmology; Pathology; Physiology; Retina; Retinal Diseases; To | 1964 |
THE PATHOLOGY OF CHLOROQUINE RETINOPATHY.
Topics: Black People; Carotid Artery Diseases; Chloroquine; Choroid; Ophthalmology; Pathology; Retina; Retin | 1964 |
OBSERVATIONS ON EXPERIMENTAL CHLOROQUINE RETINOPATHY.
Topics: Adenosine Triphosphatases; Chloroquine; Electrons; Electroretinography; Microscopy; Microscopy, Elec | 1964 |
[RETINOPATHY FOLLOWING PROLONGED CHLOQUINE (NIVAQUINE) USE].
Topics: Chloroquine; Electroretinography; Ophthalmology; Retina; Retinal Diseases; Scotoma; Toxicology | 1964 |
CHLOROQUINE RETINOPATHY AND ITS INCIDENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS.
Topics: Arteriosclerosis; Arthritis; Arthritis, Rheumatoid; Chloroquine; Diagnosis; Geriatrics; Incidence; K | 1964 |
RETINOPATHY RESULTING FROM PROLONGED USE OF NIVAQUINE.
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Humans; Lupus Erythematosus, Sys | 1964 |
[THE INCIDENCE OF CHLOROQUINE RETINOPATHY IN PATIENTS WITH RHEUMATOID ARTHRITIS].
Topics: Arthritis; Arthritis, Rheumatoid; Chloroquine; Incidence; Retinal Diseases; Retinitis; Toxicology | 1964 |
EXPERIMENTAL INVESTIGATION OF THE MORPHOGENESIS OF CHLOROQUINE RETINOPATHY.
Topics: Cats; Chloroquine; Eye Diseases; Histocytochemistry; Morphogenesis; Pathology; Pharmacology; Researc | 1965 |
OCULAR COMPLICATIONS OF CHLOROQUINE THERAPY.
Topics: Arthritis, Rheumatoid; Blindness; Chloroquine; Collagen Diseases; Cornea; Corneal Opacity; Drug Ther | 1965 |
STUDIES ON CHLOROQUINE RETINOPATHY IN RABBITS.
Topics: Animals; Chloroquine; Pathology; Rabbits; Research; Retinal Diseases; Retinitis Pigmentosa; Toxicolo | 1965 |
RETINOPATHY FOLLOWING THE USE OF CHLOROQUINE AND ALLIED SUBSTANCES.
Topics: Chloroquine; Cornea; Drug Hypersensitivity; Eye Diseases; Retina; Retinal Diseases; Retinal Pigments | 1965 |
[RETINOPATHY CAUSED BY THE USE OF CHLOROQUINE AND RELATED DRUGS].
Topics: Chloroquine; Drug Therapy; Eye Diseases; Retina; Retinal Diseases; Toxicology | 1965 |
[CHLOROQUINE RETINOPATHY].
Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Retina; Retinal Diseases | 1965 |
[HYPERPIGMENTATION AND RETINOPATHY CAUSED BY CHLOROQUINE DIPHOSPHATE].
Topics: Chloroquine; Humans; Hyperpigmentation; Pigmentation Disorders; Retinal Diseases; Toxicology | 1965 |
Retinopathy following chloroquine therapy.
Topics: Chloroquine; Disease; Lupus Erythematosus, Systemic; Retina; Retinal Diseases | 1959 |
[Retinopathy after use of chloroquine (Nivaquine)].
Topics: Chloroquine; Disease; Retina; Retinal Diseases | 1962 |
Chloroquine retinopathy.
Topics: Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Retina; Retinal Diseases | 1962 |
Two cases of chloroquine-induced retinal damage.
Topics: Chloroquine; Eye Injuries; Humans; Retinal Diseases | 1962 |
Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus.
Topics: Adolescent; Anticonvulsants; Antirheumatic Agents; Causality; Chloroquine; Female; Humans; Lupus Ery | 2004 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Blindness; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; S | 2004 |
Factors associated with chloroquine-induced retinopathy in rheumatic diseases.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Body Weight; Case-Control Studies; Chloroquine; Fema | 2004 |
Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy.
Topics: Animals; Antirheumatic Agents; Cell Culture Techniques; Chloroquine; Cytoplasmic Granules; Drug Impl | 2004 |
Factors associated with chloroquine-induced retinopathy in rheumatic diseases: comments on the article by Araiza-Casillas et al.
Topics: Antimalarials; Antirheumatic Agents; Body Height; Body Weight; Chloroquine; Humans; Retinal Diseases | 2004 |
Chloroquine-induced bull's eye maculopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Macula Lutea; Middle Aged; | 2005 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2005 |
[Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy].
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; | 2005 |
Ophthaproblem. Chloroquine or hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Humans; Male; Middle Aged; Retinal Disease | 2005 |
Retinal nerve fibre layer thickness measurements in patients using chloroquine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Body Weights and Measures; Ca | 2006 |
Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Diagnostic Imaging; Electroretinography; Female; Flu | 2006 |
[Severe chloroquine- and hydroxychloroquine-induced retinopathy].
Topics: Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Dis | 2006 |
[Retinal toxicity following chloroquine therapy].
Topics: Adult; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Retinal Diseases | 2007 |
Electrophysiologic findings in chloroquine maculopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electrodiagnosis; Electrooculography; Elec | 2007 |
[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; Child; Chloroquine; Dose-Response Relat | 2007 |
[Ocular changes and general condition in lupus erythematosus (SLE)--own observation].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Female; Humans | 2007 |
Chloroquine retinopathy: lipofuscin- and melanin-related fundus autofluorescence, optical coherence tomography and multifocal electroretinography.
Topics: Antirheumatic Agents; Arthritis; Chloroquine; Electroretinography; Female; Fluorescence; Humans; Lip | 2008 |
RETINOPATHY DURING CHLOROQUINE THERAPY.
Topics: Antirheumatic Agents; Blood Pressure; Chloroquine; Female; Humans; Liver Function Tests; Lupus Eryth | 1961 |
Chloroquine-related myasthenic syndrome with severe retinopathy.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Chloroquine; Electroretinography; Female; Humans; Lamber | 2008 |
Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Inflammation; Informed Consent; Lupu | 2007 |
Retinal toxicity of chloroquine hydrochloride administered by intraperitoneal injection.
Topics: Animals; Antimalarials; Chloroquine; Choroid; Disease Models, Animal; Injections, Intraperitoneal; M | 2008 |
Lack of correlation between melanin affinity and retinopathy in mice and cats treated with chloroquine or flunitrazepam.
Topics: Animals; Anti-Anxiety Agents; Cats; Chloroquine; Female; Flunitrazepam; Male; Melanins; Mice; Mice, | 1981 |
The use of Amsler grids in early chloroquine retinopathy.
Topics: Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Connective Tissue Diseases; Female; Humans; Kinetic | 1984 |
Electroretinogram and ocular toxicity.
Topics: Alcoholism; Animals; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Methanol; Op | 1984 |
Pattern of macular diseases in Nigerians: a preliminary report.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chloroquine; Color Perception Tests; Endophthalmit | 1983 |
Critical flicker fusion frequency in early chloroquine retinopathy.
Topics: Chloroquine; Flicker Fusion; Humans; Retinal Diseases; Visual Acuity; Visual Field Tests; Visual Fie | 1983 |
[Routine monitoring of patients treated with synthetic antimalarials].
Topics: Aged; Chloroquine; Color Perception Tests; Electroretinography; Female; Fluorescein Angiography; Fun | 1983 |
Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression.
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1984 |
Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Ciliary Body; Cornea; Drug Administration Schedule | 1983 |
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.
Topics: Arthritis, Rheumatoid; Body Weight; Chloroquine; Drug Administration Schedule; Humans; Hydroxychloro | 1983 |
Chloroquine retinopathy: is there a safe daily dose?
Topics: Adolescent; Adult; Aged; Chloroquine; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1982 |
Ocular findings in human babesiosis (Nantucket fever).
Topics: Adult; Animals; Babesiosis; Chloroquine; Collagen Diseases; Diagnosis, Differential; Female; Humans; | 1982 |
Pigmentary skin changes associated with ocular chloroquine toxicity in Ghana.
Topics: Adult; Chloroquine; Female; Ghana; Humans; Malaria; Middle Aged; Pigmentation Disorders; Retinal Dis | 1980 |
Chloroquine retinopathy in a rural hospital in Ghana.
Topics: Chloroquine; Ghana; Hospitals, General; Humans; Retinal Diseases; Rural Health; Surveys and Question | 1980 |
[The therapy with synthetic antimalarial drugs controlled by fluorescence electroretinography (author's transl)].
Topics: Chloroquine; Electroretinography; Fluorescence; Humans; Malaria; Retinal Diseases | 1980 |
[Experimental study of chloroquine retinopathy (author's transl)].
Topics: Acid Phosphatase; Animals; Chloroquine; Microscopy, Electron; Neutral Red; Rabbits; Retina; Retinal | 1981 |
Chloroquine retinopathy.
Topics: Chloroquine; Electrooculography; Humans; Retinal Diseases | 1980 |
[Macular complications of synthetic antimalarials. Apropos of a case].
Topics: Adolescent; Antimalarials; Chloroquine; Diagnosis, Differential; Eye Diseases, Hereditary; Female; H | 1995 |
Chloroquine-induced lipidosis in the rat retina: a functional and morphological study.
Topics: Animals; Chloroquine; Electroretinography; Female; Lipidoses; Rats; Rats, Wistar; Retina; Retinal De | 1995 |
No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis.
Topics: Adult; Chloroquine; Cohort Studies; Drug Administration Schedule; Female; Fibromyalgia; Humans; Mala | 1994 |
[The cornea and synthetic antimalarials].
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Corneal Diseases; Female; Humans; Male; Middle Aged; | 1994 |
Chloroquine retinopathy in Nigerian patients with heart block.
Topics: Adult; Aged; Aged, 80 and over; Chloroquine; Female; Heart Block; Humans; Malaria; Male; Middle Aged | 1993 |
Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730.
Topics: Animals; Azepines; Chloroquine; Dark Adaptation; Electroretinography; Platelet Activating Factor; Ra | 1993 |
Screening for antimalarial toxicity.
Topics: Chloroquine; Color Perception Tests; Corneal Diseases; Humans; Hydroxychloroquine; Retinal Diseases; | 1993 |
Chloroquine: consideration of maximum daily dose (3.5 mg/kg ideal body weight) prevents retinopathy.
Topics: Body Weight; Chloroquine; Humans; Lupus Erythematosus, Discoid; Retinal Diseases | 1996 |
Lipidemic effect as a manifestation of chloroquine retinotoxicity.
Topics: Animals; Chloroquine; Eye Enucleation; Lipids; Lipoproteins; Male; Microscopy, Electron; Phospholipi | 1995 |
Chloroquine retinopathy.
Topics: Antimalarials; Chloroquine; Humans; Retinal Diseases | 1997 |
Eye damage from chloroquine as an antimalarial: misuse makes safe medicines unsafe.
Topics: Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Male; Middle Aged; Retinal Diseases; Uganda | 1997 |
[The therapy of systemic lupus erythematosus].
Topics: Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 1997 |
Amyloid precursor protein, A beta and amyloid-associated proteins involved in chloroquine retinopathy in rats--immunopathological studies.
Topics: Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antibodies, Monoclonal; Cat | 1997 |
[Maculopathy in long-term chloroquine therapy].
Topics: Arthritis, Rheumatoid; Chloroquine; Computer Graphics; Dose-Response Relationship, Drug; Electroreti | 1998 |
Current concepts in monitoring patients on antimalarials.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Monitoring, Physiologic; Practice Guidelines | 1998 |
Profiles of serum proteins and free amino acids associated with chloroquine retinopathy.
Topics: Amino Acids; Animals; Antimalarials; Blood Proteins; Chloroquine; Rabbits; Retina; Retinal Diseases | 1998 |
[Ophthalmologic monitoring in chloroquine therapy].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Drug Monitoring; Humans; Patient Care Team; Retina | 1998 |
Detection of color vision defects in chloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Case-Control Studies; Chloroquine; Color Perception T | 1999 |
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Female; | 1999 |
More thoughts about antimalarials: should one prescribe chloroquine?
Topics: Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, | 1999 |
Ocular toxicity of chloroquine among Thai patients.
Topics: Adolescent; Adult; Aged; Child; Chloroquine; Female; Humans; Male; Middle Aged; Retinal Diseases; Re | 1999 |
Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction.
Topics: Adaptation, Ocular; Aged; Antirheumatic Agents; Chloroquine; Color Vision Defects; Electroretinograp | 2000 |
Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?
Topics: Aged; Aminoquinolines; ATP-Binding Cassette Transporters; Chloroquine; Genetic Predisposition to Dis | 2001 |
Case report: Retinopathy after malaria prophylaxis with chloroquine.
Topics: Antimalarials; Chloroquine; Female; Humans; Malaria; Middle Aged; Retinal Diseases | 2001 |
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse | 2002 |
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological | 2002 |
[Acquired colour-vision-deficiencies caused by side-effects of pharmacotherapy (author's transl)].
Topics: Antipsychotic Agents; Chloramphenicol; Chloroquine; Chlorpropamide; Color Vision Defects; Contracept | 1977 |
Drug-induced retinal lipidosis: differential susceptibilities of pigment epithelium and neuroretina toward several amphiphilic cationic drugs.
Topics: Animals; Chloroquine; Female; Hexestrol; Inclusion Bodies; Lipidoses; Male; Microscopy, Electron; Pi | 1978 |
Chloroquine retinopathy in the rhesus monkey.
Topics: Animals; Chloroquine; Eye; Haplorhini; Humans; Macaca mulatta; Retina; Retinal Diseases; Time Factor | 1978 |
[Functional exploration of the perimacular and macular retinal region by means of flicker E.R.G. and the determination of perceptive fusion thresholds of an intermittent light (De Lange's curve)].
Topics: Adult; Chloroquine; Electroretinography; Ethambutol; Flicker Fusion; Humans; Macula Lutea; Methods; | 1975 |
[Postnatal development of the rat retina under DNS-inhibitor (chloroquinediphosphate) mediation (author's transl)].
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Nucleus; Chloroquine; DNA Replication; Inclusi | 1975 |
Long-term course of chloroquine retinopathy after cessation of medication.
Topics: Adult; Aged; Chloroquine; Color Perception Tests; Female; Fluorescein Angiography; Follow-Up Studies | 1979 |
[Chloroquine in human ocular tissues (author's transl)].
Topics: Adult; Chloroquine; Eye; Female; Humans; Retinal Diseases | 1979 |
[Toxic retinopathies].
Topics: Chloroquine; Copper; Digitalis Glycosides; Epinephrine; Ethambutol; Humans; Immunosuppressive Agents | 1979 |
[A case of chloroquine retinopathy during malaria prophylaxis in an adult].
Topics: Aged; Chloroquine; Humans; Malaria; Male; Retinal Diseases | 1979 |
[Experimental study of chloroquine retinopathy. Report 2. Changes of visual field and light reflex threshold caused from chloroquine injections and its electron microscopic findings (author's transl)].
Topics: Animals; Chloroquine; Rabbits; Reflex, Pupillary; Retina; Retinal Diseases; Visual Fields | 1977 |
Prolonged malaria prophylaxis.
Topics: Chloroquine; Humans; Malaria; Retinal Diseases; Time Factors | 1977 |
Chloroquine retinopathy.
Topics: Adult; Chloroquine; Female; Humans; Lupus Erythematosus, Discoid; Retinal Diseases | 1977 |
Prolonged malaria prophylaxis.
Topics: Chloroquine; Humans; Malaria; Retinal Diseases | 1978 |
Delayed onset chloroquine retinopathy: case report.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Macula Lutea; Middle Aged; Retina; Re | 1978 |
[Electrophysiological studies on a case of chloroquine retinopathy (author's transl)].
Topics: Adult; Chloroquine; Electroretinography; Female; Humans; Retinal Diseases | 1976 |
[The ERG in chloroquine retinopathy (author's transl)].
Topics: Adult; Child; Chloroquine; Electroretinography; Female; Humans; Male; Middle Aged; Retinal Diseases | 1976 |
Chloroquine: a review.
Topics: Arthritis, Rheumatoid; Chloroquine; Female; Humans; Middle Aged; Retinal Diseases | 1976 |
Chloroquine retinopathy in patients with rheumatoid arthritis.
Topics: Age Factors; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; M | 1976 |
Peripheral visual field restriction in chloroquine retinopathy. Report of a case.
Topics: Adult; Chloroquine; Female; Fluorescein Angiography; Humans; Retinal Diseases; Visual Fields | 1976 |
Clinical importance of the electro-oculogram with special reference to the chloroquine retinopathy.
Topics: Arthritis, Rheumatoid; Chloroquine; Electrooculography; Humans; Retinal Diseases | 1976 |
Ocular manifestations of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Juvenile; Atropine; Cataract; Ch | 1975 |
Chloroquine retinopathy in the rat.
Topics: Animals; Chloroquine; Male; Rats; Retinal Diseases | 1975 |
[Chloroquine-induced retinopathy in patients with rheumatoid arthritis].
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Male; Middle Aged; Ret | 1975 |
[Eye complications in the long-term treatment with chloroquin. Study carried out in Togo].
Topics: Cataract; Chloroquine; Corneal Opacity; Eye Diseases; Female; Humans; Macular Degeneration; Malaria; | 1975 |
[Complications in chloroquin therapy].
Topics: Arthritis; Chloroquine; Collagen Diseases; Female; Fetal Diseases; Gastrointestinal Diseases; Humans | 1975 |
Effect of Gingko biloba extract (EGb 761) on chloroquine induced retinal alterations.
Topics: Animals; Chloroquine; Dark Adaptation; Disease Models, Animal; Electroretinography; Ginkgo biloba; P | 1992 |
Long-term course of antimalarial maculopathy after cessation of treatment.
Topics: Chloroquine; Follow-Up Studies; Humans; Hydroxychloroquine; Longitudinal Studies; Macula Lutea; Mala | 1992 |
[Involvement of PAF (Platelet-Activating Factor) in chloroquine-induced retinopathy].
Topics: Animals; Chloroquine; Electroretinography; Platelet Activating Factor; Rats; Retina; Retinal Disease | 1992 |
Chloroquine retinopathy.
Topics: Chloroquine; Color Perception; Humans; Hydroxychloroquine; Retinal Diseases; Vision Tests; Visual Ac | 1991 |
Is corneal deposition of antimalarial any indication of retinal toxicity?
Topics: Adult; Aged; Chloroquine; Cornea; Drug Overdose; Female; Fluorescein Angiography; Fundus Oculi; Huma | 1990 |
Value of Humphrey perimetry in the detection of early chloroquine retinopathy.
Topics: Aged; Chloroquine; Female; Humans; Prognosis; Retinal Diseases; Sensitivity and Specificity; Visual | 1989 |
The blood-retinal barrier in chloroquine retinopathy.
Topics: Aged; Blood-Retinal Barrier; Chloroquine; Female; Fluorescein Angiography; Fluorometry; Humans; Hydr | 1989 |
Chloroquine abuse and heart block in Africans.
Topics: Adult; Africa; Chloroquine; Heart Block; Humans; Male; Middle Aged; Retinal Diseases; Self Medicatio | 1989 |
Survival after chloroquine ingestion in a child.
Topics: Brain Edema; Chloroquine; Coma; Electroencephalography; Evoked Potentials; Humans; Infant; Male; Ner | 1988 |
[Retinal diseases].
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Antipsychotic Agents; Canthaxanthin; Ca | 1985 |
Experimental chloroquine retinopathy.
Topics: Animals; Cell Nucleus; Chloroquine; Fishes; Inclusion Bodies; Photoreceptor Cells; Retina; Retinal D | 1986 |
Ocular effects and safety of antimalarial agents.
Topics: Antimalarials; Chloroquine; Corneal Diseases; Drug Administration Schedule; Electrooculography; Elec | 1988 |
[Chloroquine retinopathy: preventable by monitoring the maximum daily dose].
Topics: Chloroquine; Drug Administration Schedule; Humans; Retinal Diseases | 1988 |
[Mechanisms of retinal damage in chloroquine retinopathy].
Topics: Animals; Chloroquine; Lipid Peroxides; Rabbits; Rats; Retina; Retinal Diseases | 1987 |
Dose relationships in patients with early chloroquine retinopathy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Retinal Dis | 1987 |
The sensitivity of Amsler grid testing in early chloroquine retinopathy.
Topics: Adult; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Tests | 1985 |
Delayed-onset chloroquine retinopathy.
Topics: Arthritis, Rheumatoid; Chloroquine; Electrooculography; Female; Humans; Middle Aged; Retinal Disease | 1986 |
Chloroquine retinopathy. Is fluorescein angiography necessary?
Topics: Chloroquine; Evaluation Studies as Topic; Fluorescein Angiography; Fundus Oculi; Humans; Photography | 1985 |
Antimalarial treatment of rheumatoid arthritis: 1985 status.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Drug Combinations; Gold; Humans; Hydroxychloroqui | 1985 |
Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.
Topics: Adult; Age Factors; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Middl | 1985 |
[Electrophysiologic evaluation of retinal functions in patients under chloroquine and its derivatives].
Topics: Adolescent; Adult; Child; Chloroquine; Electrooculography; Electroretinography; Female; Humans; Male | 1985 |
Chloroquine toxicity in the human eye. Histopathologic observations by electron microscopy.
Topics: Chloroquine; Ciliary Body; Eye; Eye Diseases; Female; Humans; Inclusion Bodies; Microscopy, Electron | 1972 |
[Diagnostic importance of electro-oculography in various hereditary dystrophies of the chorioretina].
Topics: Chloroquine; Electrooculography; Electroretinography; Humans; Macula Lutea; Retinal Degeneration; Re | 1974 |
Bitemporal hemianopia in chloroquine retinopathy.
Topics: Arthritis, Rheumatoid; Chloroquine; Diagnosis, Differential; Female; Fluorescein Angiography; Hemian | 1974 |
[Chloroquine and ethambutol oculopathies in Japan].
Topics: Chloroquine; Ethambutol; Female; Humans; Japan; Male; Retinal Diseases; Vision Disorders | 1974 |
[Experimental study of chloroquine retinopathy. Report 1. Influence of chloroquine intravenous injection to the visual fields and to the threshold of light reflex].
Topics: Animals; Chloroquine; Injections, Intravenous; Photic Stimulation; Rabbits; Reflex, Pupillary; Retin | 1974 |
[Adverse reactions of drugs. 5. Adverse reaction of antimalarial agents; focusing on chloroquine-induced retinal diseases].
Topics: Chloroquine; Humans; Retinal Diseases | 1974 |
Discoid lupus erythematosus.
Topics: Adult; Antimalarials; Chloroquine; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus E | 1972 |
[Chloroquine retinopathy].
Topics: Adult; Aged; Chloroquine; Color Vision Defects; Dark Adaptation; Electrooculography; Electroretinogr | 1972 |
Chloroquine as a malarial suppressive: absence of visual effects.
Topics: Administration, Oral; Adult; Chloroquine; Female; Humans; Malaria; Male; Middle Aged; Military Medic | 1973 |
[Chloroquine retinopathy. Peculiar behavior of the light sense].
Topics: Adaptation, Ocular; Adult; Angiography; Arthritis, Rheumatoid; Chloroquine; Dark Adaptation; Electro | 1972 |
[Ocular intoxication due to chloroquine and its derivatives. Importance of functional studies, ERG and EOG. Study of a series of 400 cases (1964-71)].
Topics: Chloroquine; Cornea; Electrooculography; Electroretinography; Eye Diseases; Humans; Refraction, Ocul | 1972 |
[Retinal disease due to chloroquine].
Topics: Adult; Aged; Chloroquine; Color Perception; Dark Adaptation; Electrooculography; Electroretinography | 1972 |
[Usefulness of red light profile and dark adaptation in diagnosis of chloroquine damage].
Topics: Adolescent; Adult; Age Factors; Aged; Child; Chloroquine; Color Perception; Dark Adaptation; Electro | 1972 |
Electrodiagnostic procedures in drug-induced ocular diseases.
Topics: Chloroquine; Electrodiagnosis; Electrooculography; Electroretinography; Evoked Potentials; Eye; Huma | 1973 |
[Etiology and pathogenesis of toxic side-effects of drugs on the retina (author's transl)].
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Agents; Cardiac Glycosides; Cats; Chloramphenicol; | 1973 |
[Chloroquine retinopathy and unilateral sectoral pigmentary degeneration of the retina (author's transl)].
Topics: Chloroquine; Diagnosis, Differential; Electrooculography; Female; Fundus Oculi; Humans; Middle Aged; | 1973 |
[An iatrogenic complication which must not happen again: chloroquine retinopathy].
Topics: Chloroquine; Female; Humans; Male; Retinal Diseases | 1973 |
[Diagnostic problems in chloroquine-induced central retinopathy].
Topics: Adolescent; Child; Chloroquine; Diagnosis, Differential; Female; Fundus Oculi; Humans; Male; Prognos | 1973 |
[Secondary toxic tapetoretinal dystrophy of the retina caused by delagil intoxication].
Topics: Adult; Chloroquine; Humans; Lupus Erythematosus, Systemic; Male; Retinal Degeneration; Retinal Disea | 1974 |
Chloroquine-induced ocular toxicity.
Topics: Chloroquine; Color Perception; Cornea; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; V | 1974 |
Ring maculopathies mimicking chloroquine retinopathy.
Topics: Adult; Blindness; Child; Chloroquine; Diagnosis, Differential; Female; Fluorescein Angiography; Fluo | 1974 |
[Undesired collateral effects of synthetic antimalarials].
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Leukopenia; Retinal Diseases | 1972 |
[Ocular involvement in chloroquine therapy].
Topics: Adult; Angiography; Chloroquine; Corneal Opacity; Dark Adaptation; Electroretinography; Eye Diseases | 1972 |
Present status of chloroquine retinopathy in A.R.E.
Topics: Arthritis, Rheumatoid; Chloroquine; Egypt; Female; Humans; Male; Retinal Diseases | 1971 |
[Macular lesions due to synthetic antimalarials].
Topics: Arthritis, Rheumatoid; Chloroquine; Electroretinography; Female; Humans; Middle Aged; Retinal Diseas | 1970 |